FRANKLIN LAKES, N.J.,
June 22, 2011 /PRNewswire/ -- Sanofi
(NYSE: SNY), Medco Health Solutions, Inc. (NYSE: MHS) and its
wholly owned subsidiary, United BioSource Corporation (UBC),
announced they have entered into a global, multi-year agreement to
support the real-world evidence assessments during Sanofi product
development and pre-/post-approval processes that support
improvements in the overall quality of patient care.
(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO
)
This agreement with Medco and UBC will allow Sanofi to more
precisely identify patient populations with the greatest unmet
medical need and help determine the patient populations in which
drugs are most effective; generate real-world comparative
effectiveness data to support product value that meets stakeholder
evidence requirements; and facilitate the development and
implementation of novel care models to improve practice of care,
adherence and patient outcomes.
Additionally, this framework gives Sanofi a consolidated
representation of payer, manufacturer and researcher insight
throughout the product lifecycle, and will support improved health
outcomes and deliver meaningful benefits to patients, providers and
payers.
"Some products that seemed to hold promise in early research,
might not deliver the intended results when used in real-world
practice," said Dr. Robert Epstein,
Medco's Clinical Research and Development Officer. "This
partnership will use real-world evidence to develop products that
demonstrate value in real-world settings, enabling Sanofi to
support high-quality, cost-effective care."
Jean-Pierre Lehner, Chief Medical
Officer of Sanofi, added: "Medco and UBC offer robust capabilities
to help us close the gap between R&D and the real-world
clinical setting. This work will bring transformative change to the
drug development process required to improve the quality of patient
care, while effectively meeting payer and other stakeholder
evidence requirements. Through this agreement, we will make the
leap from discovering and marketing new medicines to providing
comprehensive healthcare solutions that are proven to drive
safety, effectiveness and relative value for our stakeholders."
The agreement leverages the unique and complementary set of
capabilities from Medco and UBC in the areas of real-world
evidence, comparative effectiveness, personalized
medicine/pharmacogenomics, health economics, safety research, and
clinical/adherence support.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, rare diseases, consumer healthcare, emerging
markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Medco
Medco Health Solutions, Inc. (NYSE: MHS) is pioneering
The world's most advanced pharmacy® and
its clinical research and innovations are part of Medco making
medicine smarterâ„¢ for more than 65 million members.
With more than 24,000 employees worldwide dedicated to improving
patient health and reducing costs for a wide range of public and
private sector clients, and 2010 revenues of $66 billion, Medco ranks 34th on the 2011 Fortune
500 list and is named among the world's most innovative, most
admired and most trustworthy companies.
For more information, go to http://www.medcohealth.com.
About United BioSource Corporation
United BioSource Corporation (UBC), a wholly owned subsidiary of
Medco Health Solutions, Inc. (NYSE: MHS), is a global scientific
and medical affairs organization that partners with life science
companies to make medicine and medical products smarter for all
stakeholders in the health care landscape. UBC helps deliver
authoritative, real-world evidence to characterize product
effectiveness, address safety risk, and demonstrate value.
UBC brings together recognized scientific and industry experts,
research operations professionals, and new technologies to provide
innovative solutions across the product lifecycle. The
company is headquartered in Chevy Chase,
MD with offices in North and South
America, Europe and
Asia. For more information about UBC, visit
www.unitedbiosource.com.
Sanofi Forward Looking
Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations,
services, product development and potential, and statements
regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labeling and other
matters that could affect the availability or commercial potential
of such products candidates, the absence of guarantee that the
products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2010. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Medco Forward Looking Statements
This press release contains "forward-looking statements" as
that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements involve risks and uncertainties that
may cause results to differ materially from those set forth in the
statements. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this press release
should be evaluated together with the risks and uncertainties that
affect our business, particularly those mentioned in the Risk
Factors section of the Company's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q filed with the Securities and
Exchange Commission.
SOURCE Medco Health Solutions, Inc.